In QuotedData’s morning briefing 9 February 2022:
- NextEnergy Solar (NESF) has announced an interim dividend of 1.79 pence per ordinary share for the quarter ending 31 December 2021, to be paid on 31 March 2022. NESF will also be offering shareholders a scrip dividend alternative to this, with a reference price to be announced on 24 February 2022, with elections to be made by 4 March 2022.
- LXI REIT (LXI) has increased the target size of its proposed equity raise (announced in January) from £125m to £250m. It said that this was due to strong level of support received from investors, which already materially exceeds the new £250m maximum size of the fundraise, and the depth of its investment pipeline. It will announce the result of the raise tomorrow (10 February).
- LondonMetric Property (LMP) has acquired an urban logistics warehouse in Luton from Marcol Industrial Investments for £15.5m. The 168,000 sq ft property is located on Luton Enterprise Park, close to Luton town centre and J11A of the M1. It is let to two occupiers with a WAULT of three years. The rent of £0.7m per annum reflects a net initial yield of 4.3%. The group said that the property offers significant potential for redevelopment, which it will look to progress on expiry of leases.
- Civitas Social Housing (CSH) has reported a slight increase in NAV per share as its share buyback programme takes effect. IFRS NAV was down slightly to £669.65m (September 2021: £672.88m) but up 0.3% on a per share basis to 108.78p (September 2021: 108.49p). In the financial year to date, the company has purchased 6,875,000 shares into treasury at an average price of 91.33p, at a discount to its prevailing NAV per share. The impact of the share repurchases at 31 December 2021 has been to enhance IFRS NAV per share by 0.19p. A dividend of 1.3875p per share was declared and paid during the final quarter of 2021.
- River & Mercantile UK Micro Cap (RMMC) acknowledged that its manager George Ensor is now also manager of the ES River and Mercantile UK Equity Smaller Companies Fund. this follows the departure of Dan Hanbury from River & Mercantile.
- Syncona (SYNC) says that Freeline Therapeutics is due to report encouraging data from its trial of a therapy (FLT190) for Fabry disease.
We also have full year results from BlackRock Sustainable American Income and a corporate update from Strategic Equity Capital.